Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Delaware for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Delaware only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Delaware (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jinsong Zhang (NPI 1215196027)

Field	Value
Entity Type	Individual
Organization	Jinsong Zhang
Address	1100 Forrest Ave
City	Dover
State	DE
ZIP	19904
Taxonomy	Rheumatology Physician
NPI Enumerated	June 6, 2008

Payer Source	Total Paid
Medicare	$3.5M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in scale: lifetime Medicare revenue is $3.5M while Medicaid revenue is listed as none (no Medicaid billing on file), indicating the practice’s revenue and service footprint are concentrated in the Medicare population. Analysts should treat Medicare as the dominant commercial data source when assessing utilization and contracting risk for this NPI.

Revenue is highly concentrated in a small set of biologic drug codes: the precomputed top three Medicare codes account for 52.2% of the provider’s total Medicare revenue. Those top three codes are J0129 ($716.1K revenue, 20.4% of total Medicare revenue), J0897 ($641.5K revenue, 18.2% of total Medicare revenue), and J1602 ($478.5K revenue, 13.6% of total Medicare revenue), which together drive over half of Medicare payments to this NPI.

The service mix points to an infusion-heavy rheumatology practice that administers high-cost biologics on site: the top revenue drivers are J0129 (abatacept), J0897 (denosumab), J1602 (golimumab) and other injectable biologics such as J3111 and J0717. The presence of chemotherapy administration codes 96401 (1.1K claims; $60.4K revenue, 1.7%) and 96413 (636 claims; $59.8K revenue, 1.7%) further indicates the practice also bills for parenteral therapy administration, suggesting an operational model built around an infusion suite or nurse-administered injectables.

The provider is a national high-volume outlier on a subset of codes: J0897 ranks #63 of 10057 providers nationally (99th percentile; extreme outlier), marking denosumab administration as far above typical national volume for this code. Likewise, chemotherapy administration code 96401 ranks #48 of 3868 providers nationally (99th percentile; extreme outlier), which signals atypically high utilization of infusion/administration services relative to peers.

Multiple biologic drug codes show strong competitive standing nationally rather than modest participation: J1602 ranks #65 of 1041 providers nationally (94th percentile; typical, unremarkable volume for this code), J3111 ranks #51 of 970 providers nationally (95th percentile; typical, unremarkable volume for this code), and J1745 ranks #85 of 1352 providers nationally (94th percentile; typical, unremarkable volume for this code). These high percentiles across several injectable biologics indicate a consistent pattern of above‑average volume for drug administration services among peers.

Visit-level evaluation and management codes represent a small share of Medicare revenue relative to drug and infusion codes: 99214 generated $48.9K (1.4%) and 99213 generated $17.5K (0.5%) of Medicare revenue, showing that office visits are a minor component of total billed Medicare dollars. This pattern is consistent with a practice model where infusion and drug administration drive revenue while E/M services are lower-revenue add-ons.

Several ancillary administration codes are notable relative to national peers: 96372 (627 claims; $6.3K revenue, 0.2%) ranks #1084 of 58224 providers nationally (98th percentile; notably above typical national volume for this code) and 96413 ranks #350 of 7514 providers nationally (95th percentile; notably above typical national volume for this code). These placements reinforce that the provider’s operational emphasis is on in-office administration of parenteral therapies rather than on high-volume office E/M encounters.

The NPI tenure indicates an established provider presence: the NPI was enumerated on 2008-06-06 (~18 years ago), suggesting long-running operations and potential stability of referral and payer relationships in the Dover, DE market. Tenure combined with the high-volume biologic and infusion billing profile suggests an entrenched niche in rheumatology/infusion services within Medicare.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

22 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	21,700	$30	$716.1K
J0897	Injection, denosumab, 1 mg	35,640	$20	$641.5K
J1602	Injection, golimumab, 1 mg, for intravenous use	43,500	$10	$478.5K
J3111	Injection, romosozumab-aqqg, 1 mg	57,960	$10	$463.7K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	114,600	$1	$458.4K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	10,260	$30	$266.8K
J3262	Injection, tocilizumab, 1 mg	52,080	$10	$260.4K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	1,120	$50	$60.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	640	$90	$59.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	540	$90	$48.9K

Showing 1–10 of 22

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 22 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Delaware Distribution

Jinsong Zhang — 4 of 22 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Delaware

Full comparison — all codes billed, vs. state median

22 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	2	10	11,030	$30	$432.5K
J0717	5	10	98,800	$1	$376.8K
J3111	1	10	29,930	$10	$245K
J1602	1	10	21,050	$10	$238.8K
J3262	2	10	52,080	$1	$226.2K
J1745	2	10	3,610	$30	$134.3K
J0897	3	60	3,360	$20	$132.9K
96413	4	30	280	$100	$36.6K
99214	300	1,830	150	$80	$25.5K
96401	3	30	110	$60	$18.4K

Showing 1–10 of 22

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jinsong Zhang, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Yvan Maque Acosta	DE	Rheumatology Physician	$1.3M	$0
Robert Moyer	DE	Rheumatology Physician	$1.3M	$0
Infusion Solutions Of Delaware	DE	Specialist	$0	$410K
Surjeet Dheer	DE	Rheumatology Physician	$382.7K	$0
Taras Yurchenko	DE	Medical Physician Assistant	$317.3K	$0

Nearby Providers

Other providers in the same ZIP code as Jinsong Zhang, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bayada Home Health Care, Inc.	DE	Home Health Agency	$0	$37.9M
At Home Infucare, LLC	DE	Home Health Agency	$0	$28.5M
Amazing Home Care Agency	DE	Home Health Agency	$0	$18.7M
Dedicated To Women Ob-gyn, P.A.	DE	Obstetrics & Gynecology Physician	$0	$11.1M
Help At Home Of Delaware, LLC	DE	In Home Supportive Care Agency	$0	$10.7M
A Center For Mental Wellness, Inc.	DE	Mental Health Counselor	$0	$9.9M
State Of Delaware	DE	Case Management Agency	$0	$9.2M
West Dover Dental, LLC	DE	Dentist	$0	$9M
Americare Home Solutions	DE	In Home Supportive Care Agency	$0	$8.4M
Vicdania Health Services LLC	DE	Home Health Agency	$0	$7.4M

Jinsong Zhang — Billing Profile & Reimbursement Data

Sign up for Jinsong Zhang — Billing Profile & Reimbursement Data policy alerts

Jinsong Zhang — Billing Profile & Reimbursement Data

Sign up for Jinsong Zhang — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References